Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Faron Pharmaceuticals

1.93 EUR

-0.62 %

5,600 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-0.62 %
-8.96 %
-7.21 %
-16.09 %
-12.07 %
-9.39 %
-43.90 %
-59.88 %
-44.54 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
228.83M EUR
Turnover
167.86K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
24.10.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 24.10.2025

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.3.
2026

Annual report '25

30.3.
2026

General meeting '26

26.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
I added those cancer abbreviations to the message above. As I understand it, of those cancers, GBM and LGG are central nervous system cancers and might not be targetable with Bex. Others potentially are, but the red population (C4-type) is likely the one most likely to benefit from...
yesterday
by jerej
24
Was anyone listening to Bono on Zoom yesterday? @Jere1 already commented Two or three years ago in a webcast where the father and son appeared together, in the chat at the end, [they were asked] what they would like to see in the future? Juho said BEX’s efficacy in sarcoma (this ...
20 hours ago
by Vino Pino
20
On the other hand, glioblastoma is a cancer located in the central nervous system, and the CNS immune defense functions in a completely different way than in the rest of the body. In the central nervous system, microglial cells are responsible for the immune defense, meaning that...
yesterday
by jerej
15
These BBB-crossing antibodies can indeed be developed, for example by targeting them to the transferrin receptor, which mediates BBB penetration (e.g., Denali Therapeutics’ technology). The problem, however, is likely to be the next stage, where Clever-1 inhibition should be followed...
2 hours ago
by jerej
12
It seems that Markku’s dream of treating glioblastomas is far off. I was thinking about small molecule development instead of the antibody (Bex)-inside-a-Trojan-horse strategy, but those don’t automatically cross the BBB (blood-brain barrier) either. Modification work is something...
1 hour ago
by Vino Pino
11
linkedin.com #mds #bioinnovation | Faron Progress in cancer treatment stems from a deep understanding of biology and a commitment to pursuing answers even when they are hard to find. Faron’s work in immunology is built on decades of scientific inquiry. At the BioInnovation Forum,...
yesterday
by marmot76
11
ACC is likely a rare enough cancer that its treatment is not yet planned for phase I trials, source. “Adrenocortical carcinoma demonstrates distinct epidemiological patterns with significant geographic and demographic variations. The annual incidence ranges from 0.5 to 2.0 cases ...
yesterday
by jerej
7
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.